Literature DB >> 9344344

Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro.

J D Lindsey1, K Kashiwagi, F Kashiwagi, R N Weinreb.   

Abstract

PURPOSE: This study investigates the possibility that prostaglandins (PGs) induce changes in extracellular matrix (ECM) adjacent to ciliary muscle cells.
METHODS: Human ciliary smooth muscle cells were grown to confluence in monolayer cultures and were treated with PGF2alpha, 11-deoxy-PGE1, or PhXA85 (the nonesterified analogue of PhXA41) for 12 to 72 hours. The amount of collagens type I, III, and IV in the cultures was determined, using sandwich enzyme immunoassays. The distributions of these collagens were assessed in the PG-treated cultures by immunocytochemistry.
RESULTS: Twenty-four-hour treatment with 20 nM PGF2alpha, 11-deoxy-PGE1, or PhXA85 reduced the amount of collagen type I in extracts of the cell layer by 65+/-10%, 56+/-7%, and 46+/-7%, respectively, when compared with levels of those substances in vehicle-treated cultures. In similar fashion, collagen type III in cell layer extracts was reduced by 41+/-5%, 33+/-9%, and 3+/-5%, respectively. When the concentration of PGs was increased to 200 nM, the amount of type III collagen in the cell layer extracts was reduced by 93+/-7%, 99+/-1%, and 99+/-1%, respectively. Changes in type IV collagen in cell layer extracts after treatment with 20 nM PGs were not statistically significant. When the concentration of PGF2alpha, 11-deoxy-PGE1, or PhXA85 was increased to 200 nM, the amount of collagen type IV in the cell layer extract increased by 101+/-16%, 14+/-5%, and 89+/-11%, respectively. There were minimal changes in the staining pattern for collagen type I after 24-hour treatment with 20 nM PGs. When the PG concentration was increased to 200 nM, there were reductions in the density of collagen type I fibrils and clumping of collagen type III immunoreactive elements. The delicate lacework of collagen type IV immunoreactivity was replaced by bundles or clumps of heavy immunoreactive strands, separated by areas without immunoreactivity. These changes were present in cultures exposed to 20 nM PGs and were marked when PG concentration was increased to 200 nM.
CONCLUSION: These results indicate that PGs can induce substantial changes in the ECM around ciliary smooth muscle cells in vitro. These data support the possibility that changes in ciliary muscle ECM may contribute to increased uveoscleral outflow facility after topical PG administration.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9344344

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  29 in total

Review 1.  Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.

Authors:  Rebecca K Donegan; Raquel L Lieberman
Journal:  J Med Chem       Date:  2015-09-25       Impact factor: 7.446

Review 2.  Enhancing trabecular outflow by disrupting the actin cytoskeleton, increasing uveoscleral outflow with prostaglandins, and understanding the pathophysiology of presbyopia interrogating Mother Nature: asking why, asking how, recognizing the signs, following the trail.

Authors:  Paul L Kaufman
Journal:  Exp Eye Res       Date:  2007-10-26       Impact factor: 3.467

3.  Effect of non-steroidal anti-inflammatory ophthalmic solution on intraocular pressure reduction by latanoprost in patients with primary open angle glaucoma or ocular hypertension.

Authors:  T Chiba; K Kashiwagi; N Chiba; S Tsukahara
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

Review 4.  Effects of prostaglandin analogues on aqueous humor outflow pathways.

Authors:  Nelson S Winkler; Michael P Fautsch
Journal:  J Ocul Pharmacol Ther       Date:  2013-12-20       Impact factor: 2.671

Review 5.  Prostanoid receptor agonists for glaucoma treatment.

Authors:  Makoto Aihara
Journal:  Jpn J Ophthalmol       Date:  2021-07-06       Impact factor: 2.447

6.  Enhancement of scleral macromolecular permeability with prostaglandins.

Authors:  R N Weinreb
Journal:  Trans Am Ophthalmol Soc       Date:  2001

7.  Effect of topical prostaglandins on the biomechanics and shape of the cornea.

Authors:  Shiro Amano; Ryohei Nejima; Kenji Inoue; Kazunori Miyata
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-08-10       Impact factor: 3.117

8.  The additive effects on intraocular pressure of combining nipradilol 0.25% and latanoprost 0.005% ophthalmic solutions: a prospective, randomized, multicenter study.

Authors:  Tadahiko Tsuru; Yoshiaki Kitazawa; Masahiko Usui; Satoki Ueno; Ikuo Azuma; Kanjiro Masuda
Journal:  Jpn J Ophthalmol       Date:  2008-11-11       Impact factor: 2.447

9.  Travoprost in the management of open-angle glaucoma and ocular hypertension.

Authors:  Philippe Denis; David Covert; Anthony Realini
Journal:  Clin Ophthalmol       Date:  2007-03

10.  Bimatoprost, prostamide activity, and conventional drainage.

Authors:  Zhou Wan; David F Woodward; Clive L Cornell; Hans G Fliri; José L Martos; Simon N Pettit; Jenny W Wang; Alexander B Kharlamb; Larry A Wheeler; Michael E Garst; Kari J Landsverk; Craig S Struble; W Daniel Stamer
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-09       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.